Use of HLA genetic status to assess or select treatment of celiac disease
US10370718B2 · kind B2 · utility
0Cited by
29References
13Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Sep 29, 2015 |
| Grant date | Aug 6, 2019 |
| Priority date | — |
| Expiry date | Nov 26, 2035 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/52
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are methods of adjusting or selecting a gluten peptide therapy based on the human leukocyte antigen (HLA) genotype, in particular HLA-DQ2.5 homozygosity, of a subject having or suspected of having Celiac disease. Also provided herein are methods of identifying (e.g., diagnosing) a subject, such as a subject having or suspected of having Celiac disease and/or assessing the efficacy of treatment of Celiac disease, e.g. by determining responsiveness to a therapeutic gluten peptide composition or cytokine response, and kits relating thereto.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.